Fiore Cannabis Past Earnings Performance
Past criteria checks 0/6
Fiore Cannabis has been growing earnings at an average annual rate of 3.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 35% per year.
Key information
3.1%
Earnings growth rate
40.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 35.0% |
| Return on equity | n/a |
| Net Margin | -414.2% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Fiore Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -10 | 4 | 0 |
| 31 Mar 22 | 3 | -9 | 6 | 0 |
| 31 Dec 21 | 3 | -8 | 6 | 0 |
| 30 Sep 21 | 3 | -12 | 5 | 0 |
| 30 Jun 21 | 3 | -12 | 4 | 0 |
| 31 Mar 21 | 3 | -17 | 6 | 0 |
| 31 Dec 20 | 2 | -44 | 6 | 0 |
| 30 Sep 20 | 2 | -38 | 7 | 0 |
| 30 Jun 20 | 2 | -40 | 10 | 0 |
| 31 Mar 20 | 2 | -38 | 9 | 0 |
| 31 Dec 19 | 3 | -27 | 19 | 0 |
| 30 Sep 19 | 2 | -28 | 21 | 0 |
| 30 Jun 19 | 2 | -26 | 20 | 0 |
| 31 Mar 19 | 1 | -29 | 21 | 0 |
| 31 Dec 18 | 1 | -27 | 25 | 0 |
| 30 Sep 18 | 0 | -25 | 22 | 0 |
| 30 Jun 18 | 0 | -24 | 20 | 0 |
| 31 Mar 18 | 0 | -21 | 17 | 0 |
| 31 Dec 17 | 1 | -13 | 7 | 0 |
| 30 Sep 17 | 0 | -13 | 6 | 0 |
| 30 Jun 17 | 0 | -12 | 5 | 0 |
| 31 Mar 17 | 0 | -10 | 4 | 0 |
| 31 Dec 16 | 0 | -6 | 2 | 0 |
| 30 Sep 16 | 0 | -4 | 1 | 0 |
| 30 Jun 16 | 0 | -3 | 1 | 0 |
Quality Earnings: 2M0A is currently unprofitable.
Growing Profit Margin: 2M0A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2M0A is unprofitable, but has reduced losses over the past 5 years at a rate of 3.1% per year.
Accelerating Growth: Unable to compare 2M0A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2M0A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 2M0A's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.